Calcimedica

Calcimedica

Clinical-stage biotechnology company targeting calcium release-activated calcium (CRAC) channels to treatment of inflammatory and autoimmune disorders and organ transplant rejection

CalciMedica is a clinical-stage biotechnology company targeting calcium release-activated calcium (CRAC) channels to treatment of inflammatory and autoimmune disorders and organ transplant rejection. CalciMedica is developing treatments for COVID-19 pneumonia and acute pancreatitis.

CRAC channels play a critical role in the transport of calcium, a key messenger molecule, into many cell types. Calcium regulates biological functions and activation of CRAC channels control inflammation, vascular permeability and cell death. CRAC channel inhibitor drug Auxora was developed to treat acute inflammatory conditions such as COVID-19 pneumonia and acute pancreatitis. Drug candidate CM6325 is a potential treatment for chronic conditions such as rheumatoid arthritis and chronic pancreatitis.

Timeline

May 22, 2020
Calcimedica raises a $15,000,000 series C round from Valence Life Sciences.
January 4, 2009
Calcimedica raises a $4,000,000 series C round from Sanderling Ventures.
February 13, 2008
Calcimedica raises a $5,500,000 series B round from Sanderling Ventures.
July 31, 2007
Calcimedica raises a $1,500,000 series A round.

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
Calcimedica Series B round
5,500,000
February 13, 2008
4 Results
Results per page:
Page 1 of 1

People

Name
Role
LinkedIn

Michael Dunn

Employee

Sahand Mirzahossein

Employee

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Alex Keown
June 5, 2020
BioSpace
Biopharma and life sciences companies bolster their leadership teams and board with these Movers & Shakers.

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.